Abstract: . . .  Table 3.22: Sales forecasts for promising pipeline and recently launched compounds in R&D, 2005–11 125 Page 8 viii Table 4.23: Key players in the global respiratory market, 2001-05 130 Table 4.24: GSK’s marketed respiratory portfolio, 2004-05 133 Table 4.25: GSK’s respiratory R&D pipeline, 2006 135 Table 4.26: . . .
. . .  of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy. Page 3 iii Table of Contents The Asthma, COPD and Allergic Rhinitis Market Outlook to 2011 Executive Summary 10 Patient potential 10 Global market analysis 11 Analysis of future potential . . .
. . .  the global respiratory market, 2004–05 71 Table 2.15: Leading anticholinergic brands in the global respiratory market, 2004–05 74 Table 2.16: Sales forecasts for classes in the asthma/COPD market, 2005–11 78 Table 2.17: Breakdown of the global allergy rhinitis market by drug class, 2001–05 80 Table 2.18: Leading allergic rhinitis products in the global respiratory . . .
. . .  antihistamine brands in the global respiratory market, 2004–05 85 Table 2.20: Leading nasal corticosteroid brands in the global respiratory market, 2004–05 90 Table 2.21: Sales forecasts for allergic rhinitis classes, 2005–11 95 Table 3.22: Sales forecasts for promising pipeline and recently launched compounds in R&D, 2005–11 125 Page 8  . . .
. . .  brands in the global respiratory market, 2004–05 85 Table 2.20: Leading nasal corticosteroid brands in the global respiratory market, 2004–05 90 Table 2.21: Sales forecasts for allergic rhinitis classes, 2005–11 95 Table 3.22: Sales forecasts for promising pipeline and recently launched compounds in R&D, 2005–11 125 Page 8 viii . . .
. . .  2004-05 151 Table 4.42: Pfizer’s respiratory R&D pipeline, 2006 152 Table 4.43: Forecast sales for Pfizer’s respiratory portfolio, 2005–11 153 Table 4.44: Novartis’ marketed respiratory portfolio, 2004-05 154 Table 4.45: Novartis’ respiratory R&D pipeline, 2006 155 Table 4.46: Forecast sales for Novartis’ respiratory portfolio, 2005–11 156 . . .
--2587,6,216,3026,12937